



Bangkok Dusit Medical Services (BDMS)

Analyst Presentation 1Q22 Results

12 May 2022

Member of

Dow Jones Sustainability Indices

Powered by the S&P Global CSA


Bangkok Dusit Medical Services

Important Notice

- The information contained in this presentation is for information purposes only and does not constitute an offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for share in Bangkok Dusit Medical Services Public Company Limited ("BDMS" and shares in BDMS, "shares") in any jurisdiction nor should it or any part of it from the basis of, or be relied upon in any connection with, any contract or commitment whatsoever.
- This presentation may include information which is forward-looking in nature. Forward-looking information involve known and unknown risks, uncertainties and other factors which may impact on the actual outcomes, including economic conditions in the markets in which BDMS operates and general achievement of BDMS business forecasts, which will cause the actual results, performance or achievements of BDMS to differ, perhaps materially, from the results, performance or achievements expressed or implied in this presentation.
- This presentation has been prepared by the BDMS. The information in this presentation has not been independently verified. No representation, warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information and opinions in this presentation. None of the BDMS or any of its agents or advisors or any of their respective affiliates, advisors or representatives, shall have any liability (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation.
- This presentation is made, furnished and distributed for information purposes only. No part of this presentation shall be relied upon directly or indirectly for any investment decision-making or for any other purposes.
- This presentation and all other information, materials or documents provided in connection therewith, shall not, either in whole or in part, be reproduced, redistributed or made available to any other person, save in strict compliance with all applicable laws.


Contents







1Q22 Financial Summary



1Q22 Operational Recap and Financial Summary



Key Highlights 1Q22 % Chg % to Revenue 42% **Operating income** THB 23,159 mm **Hospital revenue** 45% THB 22,165 mm **Breakdown by nationality** Thai 38% 78% International 72% 22% **Breakdown by location Bangkok & Vicinity** 45% 57% **Outside Bangkok** 44% 43% Breakdown by type of patients **Outpatients** 30% 45% 55% **Inpatients** 54%

Remark: - Operating income is calculated from hospital revenue + revenue from sales of goods + other income

- All operational statistics are from BDMS management report
- Margin was calculated as a percentage of operating income

Profitability and Ratio


(THB mm)	1Q22	1Q21	Chg. (yoy)
EBITDA	6,173	3,527	75%
EBITDA margin	26.7%	21.7%	
EBIT	4,705	1,963	140%
EBIT margin	20.3%	12.1%	
Net profit	3,443	1,339	157%
Net profit margin	14.9%	8.2%	

Commentary

- Hospital revenue increased by 42% yoy mainly from
 - COVID-19 patient revenue (~17% of hospital revenue)
 If excluding this, non COVID-19 revenue would increase
 24% yoy
 - Return of non COVID-19 Thai patients
 - Recovery of both fly-in and expatriate patients
- EBITDA increased by 75% yoy from higher operating income and continued cost saving program




BDMS Response to COVID-19 and Outlook




BDMS Response to COVID-19



Our Continued Response to COVID-19 during 1Q22







COVID-19 Testing Volume Trend





^{*} COVID-19 testing included PCR, Rapid Antibody and Rapid Antigen


Hospital Occupancy Rate



Improving Non COVID-19 Occupancy Rates








- During 1Q22, hospital occupancy rate reached 80%
 - Occupancy rate of cohort wards increased to 87% due to surge in Omicron cases
 - Occupancy rate of non COVID-19 patient wards was 76% due to increase in elective surgery and the recovery of both fly-in and expatriate patients

Transition from Pandemic to Endemic




Thailand COVID-19 Daily Cases Seen Sharp Drop in May 2022



- COVID-19 situation in Thailand is improving
- High vaccination rates help to reduce the transmission of COVID-19
- Vaccination in Thailand continues to significantly reduce levels of severe illness and death caused by circulating COVID-19 strains

COVID-19 Related Revenues Likely to Decline from 1Q22 onwards




- People with Omicron variant less likely to be hospitalized compared with Delta variant
- Government also reduced hospital reimbursement for COVID-19 treatment

Recovery of Non-Covid Patients




To Offset Declining Trend of COVID-19 Related Revenues



- Non COVID-19 patient revenues will increase from return of domestic and international patients
- Fly-in patients enter to Thailand easier after Gov't further easing some travel restrictions and quarantine requirements in May 2022*
 - *1) RT-PCR is no longer required when entering Thailand for vaccinated travelers
 - 2) Unvaccinated travelers can enter Thailand by **5-day Alternative Quarantine/AHQ** with RT-PCR on Day 5 or a **No quarantine** if they have a pre-departure RT-PCR test

Positive Momentum of International Patients since 4Q21




Key Fly-in Patients Trend





Quarterly Highlights



New Joint Venture to Operate Pharmacy Business





JV with COM7 with Total Registered Capital of THB 200 mm



- 50 years experience in healthcare business
- Own & manage 53 hospitals & 80 SAVE DRUG stores
- And drug manufacturers, laboratories and other healthcare services









New Company

COIII 7 **Subsidiary** 40%

- A listed company in **Thailand**
- **Expertise in managing** retail business selling IT related products with 900+ stores nationwide

- A new JV company will operate a new brand drugstore in shopping malls and standalone outlets nationwide
- It will offer a variety of healthcare products including medicine, medical supply & equipment, wellness, sports & fitness and other IT related to healthcare products
- Target to open 50 stores within 3 years

BDMS Sustainability Update



Embracing ESG Aspects into Business Process



BEYOND EXCELLENCE

Deliver beyond excellent healthcare services with integrity, transparency, privacy and compliance

Participate in Corporate Sustainability Assessment 2022
 (e.g. S&P-DJSI, SET-THSI)



DEVELOPMENTAL INNOVATION

Execute innovative healthcare services through innovation culture & global collaboration

- BDMS Award 2022 under concept of Healthcare Ecosystem with total of 281 high potential innovation proposals
- Sourcing for innovative projects through Startup
 Engagement with the concept of BDMS Smart Healthcare
 i.e. Patient Journey, Bed Management, Health Tracker



MEANINGFUL SUSTAINABLE ENGAGEMENT

Ensure sustainable operations on the basis of eco-friendly healthcare with maximal human capital potential

- Climate mitigation: Care the Bear in collaboration with SET (802 ton CO2 equivalent reduced as of March 2022 YTD)
- BDMS Green Hospital: Training with pilot hospitals to improve environmental sustainability and LEED preparation
- Office Syndrome Prevention for all stakeholders




SOCIAL CONTRIBUTION

Uplift healthcare accessibility & health literacy of the community & society

 CPR & First Aid knowledge sharing throughout BDMS network targeting 5,000 communities' members



Operational Statistics




Operating Income Growth






COVID-19 Revenue Contribution to Hospital Revenue



3Q21



Commentary

1Q21

- 1Q22 Operating income increased significantly by 42% yoy mainly from
 - Hospital revenue increased by 45% yoy from

2Q21

Higher number of COVID-19 patients due to the surge in Omicron cases

4Q21

A return of non COVID-19 Thai patients and recovery of both fly-in and expatriate patients

1Q22


■ If excluding revenue from COVID-19 related services, non COVID-19 revenue would increase 24% yoy and 2% qoq

Thai and International Patients






(%YoY)




Top 5 Nationality Contribution in 1Q21

% to hospital revenue



Revenue Contribution by Nationality

% to hospital revenue




Commentary

- In 1Q22, Revenue from Thai patients and inter patients increased by 38% and 72% yoy, respectively
 - Recovery of fly-in patients mainly from the Middle East
 +256% and CLMV +58% yoy
 - Growth of expatriate patients from Germany +112%,
 UK +62% and Japan +28% yoy

Bangkok and Outside Bangkok





In 1Q22, Revenue from hospitals in Bangkok increased by 45% yoy (7% qoq) while revenue from outside Bangkok increased 44% yoy (5% qoq)


Patient Mix






Revenue Contribution by Patient Types

% to hospital revenue



1Q21 Patient Revenue by Payor



- Contract patients increased from 8% in 1Q21 to 13% in 1Q22 due to an increase in Universal Coverage for Emergency Patients (UCEP) patients from COVID-19
- However, since March 16,2022, those with mild Covid-19 symptoms (Green category) will no longer be eligible for free treatment under UCEP


^{*} Including Universal Coverage for Emergency Patients (UCEP)

Patient Volume and Occupancy Rate












Occupancy Rate Based on Available Beds



Average Daily Census (ADC)



Average Length of Stay (days)




Remarks:- Excluding hospitels and field hospital

- Including social security patients while excluding new born patients




Financial Highlights




Diversified Sources of Revenues and Profitability



CoE Operating Income Contribution in 1Q22



CoE Total EBITDA Contribution in 1Q22




Commentary


In 1Q22, revenue and EBITDA of Center of Excellence (CoE) contributed 47% of operating income and of total EBITDA respectively

^{*} SVNH included SVH and SNH performance

Profitability Trend








In 1Q22, Net profit was THB 3,443 million, increased by 157% yoy mainly from higher operating income, continued cost saving program and lower finance expenses


Capital Management




Capital Structure as of March 2022




Gearing Ratios: Well Within Covenants



Dividend Payment & Payout Ratio



Interest Coverage



Appendix



For More Information:- www.bangkokhospital.com

Group 1 (Bangkok&West)	Ownership	No. of Beds
1. Bangkok Hospital	100%]	329
2. Bangkok Heart Hospital	100%	54
3. Wattanosoth Hospital	、 100% L 💰	48
4. Wattanosoth International) 100%	30
5. Chiva Transitional Care	100%	52
6. Bangkok International	100% ^J	172
7. Bangkok Huahin (BHN)	100% 🥝	58
8. Bangkok Sanamchan (BSN)	100%	191
9. Thepakorn (TPK)	50.0%	100
10. Bangkok Phetchaburi (BPR)	100%	200
11. Bangkok Muangraj (BMR)	100%	140
Group 2 12. Samitivej Sukhumvit (SVH)	95.8% 🦃	275
13. Japanses by Samitivej	95.8%	30
14. Samitivej Srinakarin (SNH)	95.8%	300
15. Samitivej Sriracha (SSH)	67.4%	260
16. Samitivej Thonburi (STH)	64.0%	150
17. Samitivej Chonburi (SCH)	100%	250
18. Samitivej Chinatown (SCT)	100%	50
19. BNH Hospital (BNH)	91.5%	115
Group 3 (East)	31.370	113
20. Bangkok Pattaya (BPH)	97.3%	400
21. Bangkok Rayong (BRH)	100%	222
22. Bangkok Chanthaburi (BCH)	99.7%	200
23. Bangkok Trat (BTH)	99.8%	100
24. Koh Chang International	99.8%	3
25. Sri Rayong (SRH)	100%	195
26. Jomtien (JTH)	97.3%	232

Group 4 (North&Northeast)	Ownership	No. of Beds
27. Bangkok Chiangmai (BCM)	100%	3 139
28. Bangkok Ratchasima (BKH)	91.5%	285
29. Bangkok Pakchong (BHP)	91.5%	40
30. Bangkok Udon (BUD)	100%	105
31. Bangkok Phitsanulok (BPL)	100%	200
32. Bangkok Khon Kaen (BKN)	100%	150
33. Bangkok Chiangrai (BCR)	100%	80
Group 5		
34. Phyathai 1 (PT1)	98.6%	174
35. Phyathai 2 (PT2)	97.8%	<u>262</u>
36. Phyathai 3 (PT3)	97.6%	260
37. Phyathai Sriracha (PTS)	74.4%	295
38. Phyathai Nawamin (PTN)	99.8%	140
39. Paolo Phaholyothin (PLP)	100%	220
40. Paolo Samutprakarn(PLS)	93.7%	200
41. Paolo Chokchai 4 (PLC)	85.7%	169
42. Paolo Chokchai (PLC)	85.7%	29
43. Paolo Rangsit (PLR)	100%	128
44. Paolo Kaset (PLK)	100%	162
45. Paolo Phrapradaeng (PLD)	84.0%	60

Gro	up 6 (South&Cambodia)	<u> Dwnership</u>	No. of E	3ed:
46.	Bangkok Phuket (BPK)	99.7%	234	
47.	Bangkok Siriroj (BSI)	100%	181	
48.	Dibuk (DBK)	99.7%	75	
49.	Bangkok Hat Yai (BHH)	98.8%	193	
50.	Bangkok Samui (BSH)	100%	57	
51.	Bangkok Surat (BSR)	100%	88	
52.	Royal Phnom Penh (RPH)	100%	100	
53.	Royal Angkor International (RA	AH) 80.0%	33	
Gro	un 7: Non-Hospital			

Group /: Non-Hospital

1.	National Healthcare System	98.7%
2.	Bio Molecular Laboratories	95.0%
3.	The Medicpharma	87.1%
4.	A.N.B Laboratories	100%
5.	Save Drug Center (SDC)	100%
6.	General Hospital Products	47.2%

BDMS Wellness

1.	BDMS Wellness Clinic	100%
2.	BDMS Wellness Resort	100%
	(Mövenpick BDMS Wellness R	esort)

Thank you

BDMS IR

Email: investor@bdms.co.th

Website: https://investor.bangkokhospital.com/en